Brought to you by 
Idec buys Biogen for $6.84bn in stock
10 Dec 2003
Executive Summary
In a merger of equals, Idec Pharmaceutical (cancer and autoimmune disease therapies) is buying Biogen (autoimmune and cancer therapeutics) for stock worth $6.84bn, which is about seven times Biogen's 2002 sales. The combined entity, Biogen Idec Inc., will be the third largest biotech.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Idec buys Biogen for $6.84bn in stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice